Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

20.38CHF
2:44pm BST
Change (% chg)

CHF-0.16 (-0.78%)
Prev Close
CHF20.54
Open
CHF20.50
Day's High
CHF20.50
Day's Low
CHF20.16
Volume
81,574
Avg. Vol
283,438
52-wk High
CHF28.40
52-wk Low
CHF15.20

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,693.69
Shares Outstanding(Mil.): 131.14
Dividend: --
Yield (%): --

Financials

  IDIA.S Industry Sector
P/E (TTM): -- 105.08 37.43
EPS (TTM): -3.23 -- --
ROI: -34.68 7.78 12.14
ROE: -67.18 8.33 17.05

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

ZURICH, April 18 Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

18 Apr 2019

BRIEF-Idorsia Q1 US GAAP Net Loss Widens To CHF 106 Mln

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019

18 Apr 2019

UPDATE 2-Swiss Idorsia says 'stay tuned' for deals as it manages pipeline

* CFO says J&J was fully aware of Actelion DOJ probe (Adds details about possible deals, comments from CEO, CFO, details about Actelion settlement)

07 Feb 2019

BRIEF-Idorsia: First Patient Recruited Into React - Phase 3 Registration Study With Clazosentan

* ANNOUNCES FIRST PATIENT RECRUITED INTO REACT - PHASE 3 REGISTRATION STUDY WITH CLAZOSENTAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Feb 2019

BRIEF-Idorsia Starts Multiple-Dose Efficacy And Safety Study With Cenerimod For Treatment Of Systemic Lupus Erythematosus

* IDORSIA INITIATES A MULTIPLE-DOSE EFFICACY AND SAFETY STUDY WITH CENERIMOD FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

07 Jan 2019

Earnings vs. Estimates